Is Theriva Biologics, Inc. (TOVX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 24.3% / 30% | 179.9% / 30% | 51.5% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 24.3% / 33% | 179.9% / 33% | 51.5% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 4.4% / 33% | 32.8% / 33% | 9.4% / 33% | N/A | ✓ HALAL |
| S&P | 24.3% / 33% | 179.9% / 33% | 51.5% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 4.4% / 33% | 32.8% / 33% | 9.4% / 50% | N/A | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -137.8% | |
| Return on Assets (ROA) | -25.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$17M |
| Free Cash Flow | -$17M |
| Total Debt | $3M |
| Debt-to-Equity | 17.1 |
| Current Ratio | 1.7 |
| Total Assets | $38M |
Price & Trading
| Last Close | $0.22 |
| 50-Day MA | $0.19 |
| 200-Day MA | $0.32 |
| Avg Volume | 10.3M |
| Beta | 0.5 |
|
52-Week Range
$0.16
| |
About Theriva Biologics, Inc. (TOVX)
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Theriva Biologics, Inc. (TOVX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Theriva Biologics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Theriva Biologics, Inc.'s debt ratio?
Theriva Biologics, Inc.'s debt ratio is 24.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 4.4%.
What are Theriva Biologics, Inc.'s key financial metrics?
Theriva Biologics, Inc. has a market capitalization of $9M. Return on equity stands at -137.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.